Long COVID: Difference between revisions
Line 38: | Line 38: | ||
!Source !! Terms!! Definition | !Source !! Terms!! Definition | ||
|- | |- | ||
| WHO||align="center"|post-COVID-19 condition||align="center"| | | WHO||align="center"|[[post-COVID-19 condition]]||align="center"| | ||
*[[Post COVID-19 condition]]''' occurs in individuals with a history of probable or confirmed [[SARS-CoV-2 infection]], usually 3 months from the onset of [[COVID-19]] with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis. | *[[Post COVID-19 condition]]''' occurs in individuals with a history of probable or confirmed [[SARS-CoV-2 infection]], usually 3 months from the onset of [[COVID-19]] with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis. | ||
*Common symptoms include [[fatigue]], [[shortness of breath]], [[cognitive dysfunction]] and generally have an impact on everyday functioning. | *Common symptoms include [[fatigue]], [[shortness of breath]], [[cognitive dysfunction]] and generally have an impact on everyday functioning. | ||
Line 48: | Line 48: | ||
*Even people who are not hospitalized and who have a mild [[illness]] can experience persistent or late symptoms." | *Even people who are not hospitalized and who have a mild [[illness]] can experience persistent or late symptoms." | ||
|- | |- | ||
| Nature||align="center"| | | Nature||align="center"|[[Post-acute COVID-19]]||align="center"| | ||
* Persistent [[symptom]]s and/or delayed or long-term [[complications]] of [[SARS-CoV-2]] infection beyond 4 weeks from the onset of [[symptoms]]. | * Persistent [[symptom]]s and/or delayed or long-term [[complications]] of [[SARS-CoV-2]] infection beyond 4 weeks from the onset of [[symptoms]]. | ||
|- | |- | ||
| Lancet||align="center"| | | Lancet||align="center"|[[long COVID]]||align="center"| | ||
*Multiorgan [[symptoms]] after [[COVID-19]] are being reported by increasing numbers of patients. | *Multiorgan [[symptoms]] after [[COVID-19]] are being reported by increasing numbers of patients. | ||
*They range from [[cough]] and [[shortness of breath]] to [[fatigue]], [[headache]], [[palpitations]], [[chest pain]], joint pain, physical limitations, [[depression]], and [[insomnia]], and affect people of varying ages. | *They range from [[cough]] and [[shortness of breath]] to [[fatigue]], [[headache]], [[palpitations]], [[chest pain]], joint pain, physical limitations, [[depression]], and [[insomnia]], and affect people of varying ages. | ||
Line 57: | Line 57: | ||
*So-called [[long COVID]] is a burgeoning health concern and action is needed now to address it. | *So-called [[long COVID]] is a burgeoning health concern and action is needed now to address it. | ||
|- | |- | ||
| Nice||align="center"| | | Nice||align="center"|[[long COVID]]||align="center"| | ||
*[[Signs]] and [[symptoms]] that develop during or after an [[infection]] consistent with [[COVID-19]], continue for more than 12 weeks and are not explained by an alternative [[diagnosis]]. | *[[Signs]] and [[symptoms]] that develop during or after an [[infection]] consistent with [[COVID-19]], continue for more than 12 weeks and are not explained by an alternative [[diagnosis]]. | ||
|- | |- | ||
| Scientific American||align="center"| | | Scientific American||align="center"|[[Long Haul COVID]]||align="center"| | ||
* Individuals whose [[symptoms]] persist or develop outside the initial viral [[infection]], but the duration and pathogenesis are unknown. | |||
|- | |- | ||
| Royal Society||align="center"| | | Royal Society||align="center"|???||align="center"| | ||
* The onset of persistent or recurrent episodes of one or more of the following symptoms, within x* weeks of infection with [[SARS-CoV-2]] and continuing for y* weeks or more: | * The onset of persistent or recurrent episodes of one or more of the following symptoms, within x* weeks of infection with [[SARS-CoV-2]] and continuing for y* weeks or more: | ||
**severe [[fatigue]], reduced [[exercise capacity]], [[chest pain]] or heaviness, [[fever]], [[palpitations[[, [[cognitive impairment]], [[anosmia]] or [[ageusia]], [[vertigo]] and [[tinnitus]], [[headache]], [[peripheral neuropathy]], metallic or bitter [[taste]], [[skin rash]], [[joint pain]] or swelling. | **severe [[fatigue]], reduced [[exercise capacity]], [[chest pain]] or heaviness, [[fever]], [[palpitations[[, [[cognitive impairment]], [[anosmia]] or [[ageusia]], [[vertigo]] and [[tinnitus]], [[headache]], [[peripheral neuropathy]], metallic or bitter [[taste]], [[skin rash]], [[joint pain]] or swelling. | ||
*Maximum period between acquisition of the infection (if known) and the onset of [[symptoms]], and the minimum duration of [[symptoms]], should be specified in the definition. | *Maximum period between acquisition of the infection (if known) and the onset of [[symptoms]], and the minimum duration of [[symptoms]], should be specified in the definition. | ||
|- | |- | ||
| Haute Autorité de santé, France||align="center"| | | Haute Autorité de santé, France||align="center"|???||align="center"| | ||
*Three criteria: | *Three criteria: | ||
**Having presented with symptomatic form of [[COVID-19]] | **Having presented with symptomatic form of [[COVID-19]] |
Revision as of 11:38, 18 March 2022
WikiDoc Resources for Long COVID |
Articles |
---|
Most recent articles on Long COVID |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Long COVID at Clinical Trials.gov Clinical Trials on Long COVID at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Long COVID
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Long COVID Discussion groups on Long COVID Patient Handouts on Long COVID Directions to Hospitals Treating Long COVID Risk calculators and risk factors for Long COVID
|
Healthcare Provider Resources |
Causes & Risk Factors for Long COVID |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
For COVID-19 main page, click here
For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mitra Chitsazan, M.D.[2]
Synonyms and keywords: Long COVID Syndrome, long COVID, long-haul COVID, post-COVID-19 condition, post-COVID-19 syndrome, post-acute sequelae of COVID-19 (PASC), chronic COVID syndrome (CCS), Long-hauler COVID-19, Long-COVID, Long-tail COVID, Long-haulers, Post-acute COVID-19 syndrome, Acute post-COVID symptoms, Long post-COVID symptoms Persistent post-COVID symptoms, Post-acute COVID-19, On-going symptomatic COVID-19, Chronic COVID-19
Overview
- Shortly after the COVID-19 pandemic onset, emerging studies showed that a considerable proportion of patients with COVID-19 might exhibit sustained postinfection sequelae.
Historical Perspective
- The term ‘Long COVID’ was first used as a Twitter hashtag by a patient who was not recovering from COVID-19. [1] This patient-made term soon became a widely accepted concept by both the public and medical professionals.
- Currently, this condition is known by a variety of names, including long COVID, long-haul COVID, post-COVID-19 condition, post-COVID-19 syndrome, post-acute sequelae of COVID-19 (PASC), or chronic COVID syndrome (CCS).
- This condition is listed in the ICD-10 classification as post-COVID-19 condition since September 2020.
Definition
- On October 6, 2021, World Health Organization (WHO) released a clinical case definition of the post-COVID-19 condition through a robust, protocol-based methodology (Delphi consensus), which engaged a diverse group of representative patients, patient-researchers, external experts, WHO staff, and other stakeholders from multiple geographies. [2] It was acknowledged that this definition may change with emerging new evidence and continuously evolving our understanding of the consequences of COVID-19.
- According to WHO clinical case definition, the post-COVID-19 condition is defined as: [2]
- Post COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis.
- Common symptoms include fatigue, shortness of breath, cognitive dysfunction and generally have an impact on everyday functioning.
- Symptoms may be new-onset following initial recovery from an acute COVID-19 episode or persist from the initial illness.
- Symptoms may also fluctuate or relapse over time.
- A separate definition may be applicable for children.
- Notes: There is no minimum number of symptoms required for the diagnosis; though symptoms involving different organs systems and clusters have been described.
- A summary of some published/available definitions of the post-COVID-19 condition include:
Source | Terms | Definition |
---|---|---|
WHO | post-COVID-19 condition |
|
CDC | Long COVID | |
Nature | Post-acute COVID-19 |
|
Lancet | long COVID |
|
Nice | long COVID | |
Scientific American | Long Haul COVID | |
Royal Society | ??? |
|
Haute Autorité de santé, France | ??? |
Classification
There is no established system for the classification of long COVID.
Pathophysiology
The exact pathogenesis of long COVID is not fully understood. However, a number of putative pathophysiologic mechanisms have been suggested.
- 1) Long-term tissue damage:
- Long-term tissue damage can result in the persistence of symptoms in different organs. For example:
- Respiratory symptoms
- Neurologic symptoms
- Structural and metabolic abnormalities in the brain and brainstem may be the cause of neurologic symptoms such as headache, delirium, memory loss, anosmia, and fatigue. [9]
- Fatigue
- Chronic fatigue occurs as a complex syndrome and a few mechanisms have been suggested. These include: [10] [11] [12] [9]
- Autonomic nervous system dysfunction
- Inflammation
- Channelopathies
- Inadequate cerebral perfusion
- Chronic fatigue occurs as a complex syndrome and a few mechanisms have been suggested. These include: [10] [11] [12] [9]
- Cardiovascular symptoms
- Cardiac injury occurs in a substantial proportion of patients during acute COVID-19 episodes. Resulting cardiac abnormalities (such as impaired contractile function and cardiac remodeling) and myocardial inflammation may account for symptoms such as chest pain, palpitations, and tachycardia.
- Cardiovascular and respiratory symptoms might also be due to damages of the intrathoracic chemo and mecano-receptors, which are involved in the control and regulation of respiration and heart rate. The SARS-CoV-2 neurotropism (i.e., cell invasion and damage), microcirculation or autoimmune disorders have been suggested as the possible mechanisms for such damages. This hypothesis seems to explain many dysautonomic symptoms which occur due to a dysregulated rate in respiration or heart rate. These symptoms include breathlessness, exercise intolerance, palpitations, or orthostatic malaise. [13] [11] [14]
- Long-term tissue damage can result in the persistence of symptoms in different organs. For example:
- 2) Ongoing inflammation
- Several studies have suggested the presence of an unresolved inflammation in patients recovering from COVID-19. This ongoing inflammation may result from a variety of reasons.
- 1) Viral persistence in the gastrointestinal tract: Studies have shown the persistence of the virus in the gastrointestinal tract (in the gastric and intestinal cells) after recovering from acute COVID-19 episodes due to the high expression of ACE2 receptors in these cells. Increased fecal shedding of the SARS-CoV-2 virus has been shown in some studies. [15] [16] [17] [18] This may trigger a state of immune activation and ongoing inflammation in the body and also may explain the relatively high prevalence (up to 30%) of gastrointestinal manifestations (e.g. appetite loss, nausea, vomiting, diarrhea, and abdominal discomfort) in patients with long COVID. [19] [20]
- 2) Lymphopenia: Increased levels of pro-inflammatory markers (e.g. CRP, IL-6, and D-dimer) and lymphopenia occur during acute COVID-19 episodes and have been shown to be associated with long COVID symptoms, particularly myalgia, fatigue, and joint pain. [21]
- 3) Autoimmunity: Recently, T-cells and B-cells dysfunction have been suggested to promote long COVID pathophysiology similar to [[autoimmune diseases[[. [22]
- 4) Other mechanisms
- In a recent study using Invasive Cardiopulmonary Exercise Testing (iCPET), the pathophysiologic mechanism of exercise intolerance in post-COVID-19 long-haul syndrome has been investigated. [23] The results of the study showed that patients without cardiopulmonary disease who have recovered from COVID-19 had a marked decrease in peak oxygen consumption] and an exaggerated hyperventilation response during exercise. This means that patients who have recovered from COVID-19 had:
- Reduced peak exercise aerobic capacity
- Impaired systemic oxygen extraction
- Abnormal ventilatory efficiency slope.
- In a recent study using Invasive Cardiopulmonary Exercise Testing (iCPET), the pathophysiologic mechanism of exercise intolerance in post-COVID-19 long-haul syndrome has been investigated. [23] The results of the study showed that patients without cardiopulmonary disease who have recovered from COVID-19 had a marked decrease in peak oxygen consumption] and an exaggerated hyperventilation response during exercise. This means that patients who have recovered from COVID-19 had:
- Several studies have suggested the presence of an unresolved inflammation in patients recovering from COVID-19. This ongoing inflammation may result from a variety of reasons.
Epidemiology and Demographics
- The reported incidence/prevalence of long COVID varies in different studies mainly due to the absence of single terminology and definition.
- A meta-analysis, including 47,910 patients (age 17-87 years), estimated that 80% of the patients with SARS-CoV-2 infections developed one or more long-term (ranging from 14 to 110 days) symptoms. [24]
- Women seem to be more commonly affected by long COVID than men. [25]
Risk Factors
- There are no established risk factors for long COVID.
- However, according to several studies, the most common risk factors for the development of long COVID may include: [24] [25] [26]
- Older age
- Female gender
- Preexisting comorbidities, such as obesity, asthma
- More severity of the acute COVID-19 episode, including a prolonged hospitalization or ICU stay
- However, emerging data suggest that even patients with a less severe initial episode of COVID-19, who had not required hospitalization, may also experience persistent symptoms of post-COVID-19 condition
- Medical complications during acute COVID-19 episode, such as secondary bacterial pneumonia, venous thromboembolism
- Presence of a higher number of symptoms in the acute COVID-19 episode (i.e. an extended spectrum of symptoms) (more than five initial symptoms)
- Increased levels of C-reactive protein and D-dimer
- Decreased lymphocyte count
Screening
There is insufficient evidence to recommend routine screening for long COVID.
Natural History, Complications, and Prognosis
- The natural history, clinical course, long-term complications, and prognosis of long COVID-19 are still not completely understood.
- Manifestations of the post-COVID-19 condition vary considerably in terms of organ involvement and severity of symptoms; however, they generally impact the everyday functioning of affected patients. [2]
- Symptoms might newly develop following initial recovery from an acute COVID-19 illness or occur as a persist from the initial episode. [2]
- Symptoms might also fluctuate or relapse over time. [2]
Diagnosis
Diagnostic Study of Choice
- According to a clinical case definition by WHO, the post-COVID-19 condition is defined as follow: [2]
- The post-COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset, with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis.
History and Symptoms
Long COVID can involve almost every organ. The most common symptoms of long COVID include: [2] [24] [27] [28]
- Neurocognitive symptoms:
- Memory impairment and Cognitive dysfunction: described by patients as “brain fog”
- Headache
- Other less common symptoms include:
Physical Examination
- In patients with cardiopulmonary symptoms, a throughout chest examination may provide a clue to the underlying condition:
- On pulmonary examination:
- Coarse crackles: a sign of fibrosis
- Dullness on percussion: a sign of pleural effusion or consolidation
- Egophony: A sign of consolidation
- Fine basilar crackles: A sign of pulmonary edema
- On cardiac examination, the following findings may provide a clue to the underlying cardiac complication:
- Orthostasis
- On pulmonary examination:
Laboratory Findings
There are no diagnostic laboratory findings associated with long COVID. Symptoms do not correlate with the serology of SARS-CoV-2.
Electrocardiography
In patients with cardiopulmonary symptoms, an ECG may be needed.
X-ray
A chest x-ray may be helpful in the diagnosis of pulmonary complications of COVID-19 such as lung damage (ie, ground glass opacities, consolidation, interlobular septal thickening) and pleural effusion.
Echocardiography or Ultrasound
In selected patients with cardiopulmonary symptoms, echocardiography may be necessary.
CT scan
In patients with cardiopulmonary symptoms, a chest CT scan may be needed.
MRI
There are no MRI findings associated with long COVID. However, a cardiac MRI may be helpful in the diagnosis of myocarditis in COVID-19 patients.
Other Imaging Findings
There are no other imaging findings associated with long COVID.
Other Diagnostic Studies
In selected patients with cardiopulmonary symptoms, Holter monitoring, cardiopulmonary exercise testing (CPET), and pulmonary function tests may be necessary.
Treatment
Due to the diversity of symptoms and their severity, the mainstay of long COVID treatment is multidisciplinary and supportive. The management should focus on supporting self-management and individualized rehabilitation. [29] [30]
Medical Therapy
- Dyspnea
- Dyspnea in long COVID patients should be treated similar to non-COVID-19 patients. General measures in the management of dyspnea in long COVID patients may include: [31]
- In the presence of any identified underlying cardiac or pulmonary disease, referral to a cardiologist or pulmonologist and appropriate pharmacotherapy may be required.
- Cough
- Cough should be managed in a similar to cough in patients with post-viral cough syndrome.
- Attention should be paid to diagnose and treat other exacerbating or contributing factors such as gastrointestinal reflux disease and asthma.
- Over-the-counter cough suppressants, including benzonatate, guaifenesin, and dextromethorphan are the mainstay of treatment.
- Cardiac injury
- Long COVID patients with evidence of cardiac injury should be referred to cardiology services.
- Patients recovering from cardiac injury with impaired functional status (eg, New York Heart Association class II or higher) should undergo cardiac rehabilitation if no contraindications are present.
- Orthostasis
- Orthostasis and dysautonomia, such as unexplained sinus tachycardia, dizziness on standing, is initially managed conservatively with compression stockings, abdominal binder, increased intake of fluid and salts, physical therapy/rehabilitation, and behavioral modifications.
- In patients with postural orthostatic tachycardia syndrome (PoTS) and inadequate response to non-pharmacological therapy, beta-blockers, ivabradine, or fludrocortisone (with blood pressure and response monitoring) might be considered.
- Olfactory/gustatory symptoms
- In most patients with a loss or decrease in sense of smell or taste, symptoms improve slowly over several weeks and do not require medical intervention. Patients may need education on food and home safety.
- In patients with persistent symptoms, olfactory training may be appropriate. If conservative management fails, referral to an otolaryngologist and specialized taste and smell clinic may also be considered.
- Fatigue
- A Consensus Guidance Statement provides practical guidance to clinicians in the treatment of fatigue in postacute sequelae of SARS‐CoV‐2 infection (PASC) patients.
- Conservative management
- 1) Initiation of an individualized and structured, titrated return to activity program (individualized rehabilitation)
- The goal of such a rehabilitation program should be restoring patients to their previous levels of activity and improve quality of life
- The titration approach ensures that patients are engaged in activities at a submaximal level to avoid exacerbation of fatigue.
- Level of activity should be adjusted according to change in fatigue-related symptoms that develop during or after activity.
- 2) Educating patients on energy conservation strategies
- 3) Encouraging a healthy diet and adequate hydration
- 4) Treatment of any underlying medical conditions such as pain, insomnia/sleep disorders (including poor sleep hygiene), and mood problems that may be contributing and/or aggravating fatigue.
- 1) Initiation of an individualized and structured, titrated return to activity program (individualized rehabilitation)
- Pharmacologic therapy and supplements
- A number of herbal remedies/supplements and pharmacologic agents have been used in the treatment of chronic fatigue in other causes of chronic illness (eg, multiple sclerosis, fibromyalgia, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), cancer, brain injury, and Parkinson's disease).
- These include: [32] [33] [34] [35] 34890036 [35]
- However, it should be noted that due to limited scientific evidence, currently there is no general consensus on routine administration of these supplements/medications. Thus, they may be considered on a case‐by‐case basis.
- Other therapeutic interventions such as acupuncture have been suggested in the treatment of fatigue.
- Conservative management
- A Consensus Guidance Statement provides practical guidance to clinicians in the treatment of fatigue in postacute sequelae of SARS‐CoV‐2 infection (PASC) patients.
- Weight loss
- In patients with long COVID, weight loss is multifactorial and may occur due to a combination of malnutrition, loss of appetite, catabolic state, swallowing difficulty, and alterations in taste and smell.
- Patients should be encouraged to eat small, frequent meals with protein and calorie supplementation. Nutrition consultation and referral to a dietician may be required in selected patients with severe weight loss.
- Psychological and emotional issues
- In patients experiencing emotional distress, mood disturbances, anxiety, or symptoms of post-traumatic stress disorder, mental health assessment and possible referral to a psychiatrist may be required.
- Alopecia
- There is no specific therapy for alopecia in COVID-19 patients, and it should be managed similarly to non-COVID-19 patients.
- In patients with concomitant malnutrition, nutritional deficiencies should be corrected.
- Insomnia
- All patients with insomnia should be educated on sleep hygiene guidelines, stimulus control instructions, and relaxation techniques. Short-term pharmacologic treatment with benzodiazepines or non-benzodiazepine hypnotics may be needed in selected patients.
Primary Prevention
The most effective measure to prevent the post-COVID-19 condition is to prevent COVID-19. These primary prevention strategies include:
Secondary Prevention
There are no established measures for the secondary prevention of long COVID.
See also
References
- ↑ Callard F, Perego E (2021). "How and why patients made Long Covid". Soc Sci Med. 268: 113426. doi:10.1016/j.socscimed.2020.113426. PMC 7539940 Check
|pmc=
value (help). PMID 33199035 Check|pmid=
value (help). - ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition Working Group on Post-COVID-19 Condition (2021). "A clinical case definition of post-COVID-19 condition by a Delphi consensus". Lancet Infect Dis. doi:10.1016/S1473-3099(21)00703-9. PMC 8691845 Check
|pmc=
value (help). PMID 34951953 Check|pmid=
value (help). - ↑ Truffaut L, Demey L, Bruyneel AV, Roman A, Alard S, De Vos N; et al. (2021). "Post-discharge critical COVID-19 lung function related to severity of radiologic lung involvement at admission". Respir Res. 22 (1): 29. doi:10.1186/s12931-021-01625-y. PMC 7819622 Check
|pmc=
value (help). PMID 33478527 PMID: 33478527 Check|pmid=
value (help). - ↑ Han X, Fan Y, Alwalid O, Li N, Jia X, Yuan M; et al. (2021). "Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia". Radiology. 299 (1): E177–E186. doi:10.1148/radiol.2021203153. PMC 7841877 Check
|pmc=
value (help). PMID 33497317 PMID: 33497317 Check|pmid=
value (help). - ↑ Bellan M, Soddu D, Balbo PE, Baricich A, Zeppegno P, Avanzi GC; et al. (2021). "Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge". JAMA Netw Open. 4 (1): e2036142. doi:10.1001/jamanetworkopen.2020.36142. PMC 7841464 Check
|pmc=
value (help). PMID 33502487 PMID: 33502487 Check|pmid=
value (help). - ↑ Liu D, Zhang W, Pan F, Li L, Yang L, Zheng D; et al. (2020). "The pulmonary sequalae in discharged patients with COVID-19: a short-term observational study". Respir Res. 21 (1): 125. doi:10.1186/s12931-020-01385-1. PMC 7245637 Check
|pmc=
value (help). PMID 32448391 PMID: 32448391 Check|pmid=
value (help). - ↑ Marvisi M, Ferrozzi F, Balzarini L, Mancini C, Ramponi S, Uccelli M (2020). "First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: Factors predicting fibrotic evolution". Int J Infect Dis. 99: 485–488. doi:10.1016/j.ijid.2020.08.054. PMC 7443096 Check
|pmc=
value (help). PMID 32841688 PMID: 32841688 Check|pmid=
value (help). - ↑ Wei J, Yang H, Lei P, Fan B, Qiu Y, Zeng B; et al. (2020). "Analysis of thin-section CT in patients with coronavirus disease (COVID-19) after hospital discharge". J Xray Sci Technol. 28 (3): 383–389. doi:10.3233/XST-200685. PMC 7369060 Check
|pmc=
value (help). PMID 32474479 PMID: 32474479 Check|pmid=
value (help). - ↑ 9.0 9.1 Maksoud R, du Preez S, Eaton-Fitch N, Thapaliya K, Barnden L, Cabanas H | display-authors=etal (2020) A systematic review of neurological impairments in myalgic encephalomyelitis/ chronic fatigue syndrome using neuroimaging techniques. PLoS One 15 (4):e0232475. DOI:10.1371/journal.pone.0232475 PMID: 32353033
- ↑ Rubin R (2020). "As Their Numbers Grow, COVID-19 "Long Haulers" Stump Experts". JAMA. 324 (14): 1381–1383. doi:10.1001/jama.2020.17709. PMID 32965460 Check
|pmid=
value (help). - ↑ 11.0 11.1 Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R; et al. (2021). "Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies". Clin Med (Lond). 21 (1): e63–e67. doi:10.7861/clinmed.2020-0896. PMC 7850225 Check
|pmc=
value (help). PMID 33243837 Check|pmid=
value (help). - ↑ Komaroff AL, Bateman L (2020). "Will COVID-19 Lead to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome?". Front Med (Lausanne). 7: 606824. doi:10.3389/fmed.2020.606824. PMC 7848220 Check
|pmc=
value (help). PMID 33537329 Check|pmid=
value (help). - ↑ Motiejunaite J, Balagny P, Arnoult F, Mangin L, Bancal C, d'Ortho MP; et al. (2020). "Hyperventilation: A Possible Explanation for Long-Lasting Exercise Intolerance in Mild COVID-19 Survivors?". Front Physiol. 11: 614590. doi:10.3389/fphys.2020.614590. PMC 7849606 Check
|pmc=
value (help). PMID 33536937 Check|pmid=
value (help). - ↑ Yong SJ (2021). "Persistent Brainstem Dysfunction in Long-COVID: A Hypothesis". ACS Chem Neurosci. 12 (4): 573–580. doi:10.1021/acschemneuro.0c00793. PMC 7874499 Check
|pmc=
value (help). PMID 33538586 Check|pmid=
value (help). - ↑ Zang R, Gomez Castro MF, McCune BT, Zeng Q, Rothlauf PW, Sonnek NM; et al. (2020). "TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes". Sci Immunol. 5 (47). doi:10.1126/sciimmunol.abc3582. PMC 7285829 Check
|pmc=
value (help). PMID 32404436 Check|pmid=
value (help). - ↑ Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H (2020). "Evidence for Gastrointestinal Infection of SARS-CoV-2". Gastroenterology. 158 (6): 1831–1833.e3. doi:10.1053/j.gastro.2020.02.055. PMC 7130181 Check
|pmc=
value (help). PMID 32142773 Check|pmid=
value (help). - ↑ Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M; et al. (2021). "Evolution of antibody immunity to SARS-CoV-2". Nature. 591 (7851): 639–644. doi:10.1038/s41586-021-03207-w. PMC 8221082 Check
|pmc=
value (help). PMID 33461210 Check|pmid=
value (help). - ↑ Lamers MM, Beumer J, van der Vaart J, Knoops K, Puschhof J, Breugem TI; et al. (2020). "SARS-CoV-2 productively infects human gut enterocytes". Science. 369 (6499): 50–54. doi:10.1126/science.abc1669. PMC 7199907 Check
|pmc=
value (help). PMID 32358202 Check|pmid=
value (help). - ↑ Cheung KS, Hung IFN, Chan PPY, Lung KC, Tso E, Liu R; et al. (2020). "Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis". Gastroenterology. 159 (1): 81–95. doi:10.1053/j.gastro.2020.03.065. PMC 7194936 Check
|pmc=
value (help). PMID 32251668 Check|pmid=
value (help). - ↑ Mao R, Qiu Y, He JS, Tan JY, Li XH, Liang J; et al. (2020). "Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis". Lancet Gastroenterol Hepatol. 5 (7): 667–678. doi:10.1016/S2468-1253(20)30126-6. PMC 7217643 Check
|pmc=
value (help). PMID 32405603 Check|pmid=
value (help). - ↑ Tavakolpour S, Rakhshandehroo T, Wei EX, Rashidian M (2020). "Lymphopenia during the COVID-19 infection: What it shows and what can be learned". Immunol Lett. 225: 31–32. doi:10.1016/j.imlet.2020.06.013. PMC 7305732 Check
|pmc=
value (help). PMID 32569607 Check|pmid=
value (help). - ↑ Karlsson AC, Humbert M, Buggert M (2020). "The known unknowns of T cell immunity to COVID-19". Sci Immunol. 5 (53). doi:10.1126/sciimmunol.abe8063. PMID 33208380 Check
|pmid=
value (help). - ↑ Singh I, Joseph P, Heerdt PM, Cullinan M, Lutchmansingh DD, Gulati M; et al. (2022). "Persistent Exertional Intolerance After COVID-19: Insights From Invasive Cardiopulmonary Exercise Testing". Chest. 161 (1): 54–63. doi:10.1016/j.chest.2021.08.010. PMC 8354807 Check
|pmc=
value (help). PMID 34389297 Check|pmid=
value (help). - ↑ 24.0 24.1 24.2 Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A; et al. (2021). "More than 50 long-term effects of COVID-19: a systematic review and meta-analysis". Sci Rep. 11 (1): 16144. doi:10.1038/s41598-021-95565-8. PMC 8352980 Check
|pmc=
value (help). PMID 34373540 Check|pmid=
value (help). Review in: Ann Intern Med. 2022 Jan;175(1):JC10 - ↑ 25.0 25.1 Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC; et al. (2021). "Attributes and predictors of long COVID". Nat Med. 27 (4): 626–631. doi:10.1038/s41591-021-01292-y. PMC 7611399 Check
|pmc=
value (help). PMID 33692530 Check|pmid=
value (help). - ↑ Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I; et al. (2021). "Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study". BMJ. 372: n693. doi:10.1136/bmj.n693. PMC 8010267 Check
|pmc=
value (help). PMID 33789877 Check|pmid=
value (help). - ↑ Cares-Marambio K, Montenegro-Jiménez Y, Torres-Castro R, Vera-Uribe R, Torralba Y, Alsina-Restoy X; et al. (2021). "Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis". Chron Respir Dis. 18: 14799731211002240. doi:10.1177/14799731211002240. PMC 7975482 Check
|pmc=
value (help). PMID 33729021 Check|pmid=
value (help). - ↑ Shah W, Hillman T, Playford ED, Hishmeh L (2021). "Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline". BMJ. 372: n136. doi:10.1136/bmj.n136. PMID 33483331 Check
|pmid=
value (help). - ↑ Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L (2020). "Management of post-acute covid-19 in primary care". BMJ. 370: m3026. doi:10.1136/bmj.m3026. PMID 32784198 Check
|pmid=
value (help). - ↑ Herrera JE, Niehaus WN, Whiteson J, Azola A, Baratta JM, Fleming TK; et al. (2021). "Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of fatigue in postacute sequelae of SARS-CoV-2 infection (PASC) patients". PM R. 13 (9): 1027–1043. doi:10.1002/pmrj.12684. PMC 8441628 Check
|pmc=
value (help). PMID 34346558 Check|pmid=
value (help). - ↑ Bouteleux B, Henrot P, Ernst R, Grassion L, Raherison-Semjen C, Beaufils F; et al. (2021). "Respiratory rehabilitation for Covid-19 related persistent dyspnoea: A one-year experience". Respir Med. 189: 106648. doi:10.1016/j.rmed.2021.106648. PMC 8511554 Check
|pmc=
value (help). PMID 34689061 Check|pmid=
value (help). - ↑ Hargreaves IR, Mantle D (2021). "COVID-19, Coenzyme Q10 and Selenium". Adv Exp Med Biol. 1327: 161–168. doi:10.1007/978-3-030-71697-4_13. PMID 34279837 Check
|pmid=
value (help). - ↑ Ouyang L, Gong J (2020). "Mitochondrial-targeted ubiquinone: A potential treatment for COVID-19". Med Hypotheses. 144: 110161. doi:10.1016/j.mehy.2020.110161. PMC 7403158 Check
|pmc=
value (help). PMID 32795832 Check|pmid=
value (help). - ↑ Gvozdjakova A, Klauco F, Kucharska J, Sumbalova Z (2020). "Is mitochondrial bioenergetics and coenzyme Q10 the target of a virus causing COVID-19?". Bratisl Lek Listy. 121 (11): 775–778. doi:10.4149/BLL_2020_126. PMID 33164536 Check
|pmid=
value (help). - ↑ 35.0 35.1 Vollbracht C, Kraft K (2021). "Feasibility of Vitamin C in the Treatment of Post Viral Fatigue with Focus on Long COVID, Based on a Systematic Review of IV Vitamin C on Fatigue". Nutrients. 13 (4). doi:10.3390/nu13041154. PMC 8066596 Check
|pmc=
value (help). PMID 33807280 Check|pmid=
value (help).